The U.S. Food and Drug Administration has approved Merck's Welireg (belzutifan) in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the adjuvant treatment of renal cell carcinoma ...
Jun 19, 2026
0
8
Belzutifan, a first-in-class drug that arose from scientific discoveries at UT Southwestern Medical Center, has been approved by the Food and Drug Administration to treat some patients with earlier-stage kidney cancers in ...
Jun 16, 2026
0
5
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2α inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component ...
Jun 15, 2026
0
4
A new Northwestern Medicine study suggests that a simple blood test could help identify which patients with head and neck cancer will be most likely to benefit from immunotherapy, according to a study published in the Journal ...
Jun 8, 2026
0
3
Previously, immature overall survival results of the NRG Oncology GY018 (NRG-GY018) trial suggested that the use of the immunotherapy drug pembrolizumab in combination with chemotherapy improved overall survival for patients ...
Jun 1, 2026
0
6
The combination of a vaccine and a drug, which both harness the immune system to attack cancer cells, has proven successful in cutting the risk of skin cancer recurrence and death by 49%, a new study shows. This reduction ...
Jun 1, 2026
0
13
As part of a clinical study, the Early Clinical Trial Unit (ECTU) at NCT/UCC Dresden tested the cancer immunotherapy IMA401 for the first time in patients with advanced solid tumors. IMA401 is a so-called bispecific T-cell ...
May 31, 2026
0
12
A new study in Cell Reports Medicine from researchers at The University of Texas MD Anderson Cancer Center identified key features that may help predict which types of rare cancers are likely to respond to immunotherapy.
May 20, 2026
0
2
The U.S. Food and Drug Administration's decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw that the drug had prolonged the lives of a third of ...
May 18, 2026
0
7
Immunotherapy has become a standard of care in treating high-risk, early-stage breast cancers, yet it has had limited success in shrinking tumors. New biomarkers that can improve outcomes for patients are urgently needed. ...
May 3, 2026
0
23
